Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC on Rembrandt sale

This article was originally published in The Tan Sheet

Executive Summary

FTC is collecting public comment through Dec. 7 on the proposed divestiture of the Rembrandt toothpaste and tooth whitening business by Procter & Gamble and Gillette, the commission announces Nov. 8. The firms, who recently merged, submitted a petition to FTC requesting that the sale of the business be approved. P&G and Gillette announced the proposed sale of the brand to Johnson & Johnson's Personal Products Company in October after FTC required the business be divested in order to maintain competition in the industry (1"The Tan Sheet" Oct. 31, 2005, p. 7)...

You may also be interested in...



Rembrandt Purchase Brings Whitening Category To J&J

Johnson & Johnson gains entry into the tooth whitening segment with the purchase of Rembrandt oral care brand from Procter & Gamble's Gillette division

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel